14 documents found, page 1 of 2

Portuguese consensus on first line treatment of moderate-to-severe psoriasis wi...

Introduction: Psoriasis (PsO) is a common chronic, inflammatory, immune-mediated disease. In 2023, a 4.4% prevalence of PsO was reported in Portugal. Currently, Tumor Necrosis Factor inhibitors (TNFi) are the recommended first-line (1 L) biologic agents in Portugal given their lower cost. However, TNFi may not be suitable for several patients. In these patients, interleukin inhibitors (ILi) should be considered...

Influence of clinical and psychosocial factors on the adherence to topical trea...

Psoriasis is a common chronic inflammatory skin disease with different manifestations, affecting the quality of life at social, emotional, and professional dimensions and requiring long-term treatment. This study aimed to investigate the effect of psychosocial and clinical factors on adherence to topical treatment in psoriasis. Self-reported measures and weighing the medicines were used to assess adherence. Psy...

Influence of psoriasis lesions' location and severity on psychosocial disabilit...

Objectives: The psychosocial impact of psoriasis is well documented. However, the contributing role of clinical disease characteristics is not satisfactorily explored. This study aimed to validate the Self-administered Psoriasis Area and Severity Index (SAPASI) to a Portuguese population (SAPASI-PT) and to perform its cross-validation, assessing how the results will generalize to an independent data set, with t...

Determinants for Drug Survival of Methotrexate in Patients with Psoriasis: 10-Y...

Introduction: Methotrexate has been used in the systemic treatment of psoriasis since 1950 and remains a first-line drug. It is important to assess the factors that influence its discontinuation. The aim of the authors was to identify determinants of drug survival of metho- trexate in patients with psoriasis. Methods: A retrospective analysis was performed concerning patients who started psoriasis treatment wit...

Idiopathic Pyoderma Gangrenosum Treated with Adalimumab: A Case of Success

Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review

Introduction: Immune checkpoint inhibitors revolutionized anti-neoplastic treatment. Recently, the European Medicines Agency and the United States Food and Drug Administration approved inhibitors of various immune checkpoints, namely the cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 and its ligand. Despite the added benefits in the treatment of several neoplasms, immune checkpoint...

Recalcitrant Acneiform Eruption Revealing Behçet’s Disease: A Case with Late bu...

Behçet's disease is a systemic vasculitis with a chronic-relapsing course, which can lead to significant morbidity and mortality. From the often-compelling challenge of making a prompt diagnosis comes the difficulty in its treatment. We report the case of a patient with an acneiform skin eruption revealing Behçet's disease that was refractory to conventional therapy and later completely responded to adalimumab....

Fatal Orbital Pyoderma Gangrenosum with Central Nervous System Involvement

Pyoderma gangrenosum is a chronic inflammatory disease characterized by the development of a painful deep ulcer with undermined borders. Head and neck are rarely affected regions of the body and also usually associated with a worse prognosis. Corticosteroids are the mainstay of treatment although available options are not specific nor completely effective in pyoderma gangrenosum. We report the case of a 46-year...

Psoriasis and comorbidities: general practitioners’ awareness

INTRODUCTION: Systemic inflammatory diseases such as psoriasis, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) are associated with an increased prevalence of cardiovascular diseases (CVD) and other comorbidities. The primary aim of this study was to assess the screening practices of general practitioners (GPs) with regard to the most frequent comorbidities in patients with psoriasis. METHODS:...

PSORIASIS IMMUNOPATHOGENESIS

Psoriasis is a common disease, whose treatment has evolved with new discoveries on its pathogenesis. Thus it becomes important to study the involved molecular and immune mechanisms to best understand current treatment and potential therapeutic targets. In this paper we aim to review current knowledge on psoriasis pathogenesis. We describe the proposed role for the immune system, the keratinocytes and the microv...